I. Hansen

MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (CIMESTRA)

Merete Lund Hetland, B Ejbjerg, Søren Jacobsen et al. · Annals of the Rheumatic Diseases · 2008 · 366 citations

Medicine, Clinical Sciences, Immunology +17

Radiographic progression and remission rates in early rheumatoid arthritis – MRI bone oedema and anti-CCP predicted radiographic progression in the 5-year extension of the double-blind randomised CIMESTRA trial

Merete Lund Hetland, K. Stengaard‐Pedersen, Peter Junker et al. · Annals of the Rheumatic Diseases · 2010 · 188 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +17

Aggressive combination therapy with intra-articular glucocorticoid injections and conventional disease-modifying anti-rheumatic drugs in early rheumatoid arthritis: second-year clinical and radiographic results from the CIMESTRA study

Merete Lund Hetland, K. Stengaard‐Pedersen, Peter Junker et al. · Annals of the Rheumatic Diseases · 2007 · 124 citations

Medicine, Clinical Sciences, Pharmacotherapy +17

Prediction of treatment response to adalimumab: a double-blind placebo-controlled study of circulating microRNA in patients with early rheumatoid arthritis

S. B. Krintel, Christian Dehlendorff, Merete Lund Hetland et al. · The Pharmacogenomics Journal · 2015 · 67 citations

Life Sciences, Clinical Sciences, Immunology +16

Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial

Mikkel Østergaard, Ronald van Vollenhoven, Anna Rudin et al. · Annals of the Rheumatic Diseases · 2023 · 52 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +17